Stock TARS TARSUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
32.29 USD -3.96% Intraday chart for Tarsus Pharmaceuticals, Inc. -7.05% +59.46%
May. 31 Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI
May. 31 Certain Options of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.
CI
Certain Options of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.
CI
Certain Common Stock of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.
CI
Tarsus to Participate in Upcoming Investor Conferences
GL
Transcript : Tarsus Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:55 PM
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
GL
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating
MT
Tarsus Pharmaceuticals : Corporate Presentation
PU
Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, vs. Street Est of $17.9M
MT
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
GL
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
GL
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals
MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
AN
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
AQ
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
GL
Tarsus Pharmaceuticals, Inc. Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-Dilutive Financing Commitment from Pharmakon
CI
Tarsus Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding
CI
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TARS Stock
  4. News Tarsus Pharmaceuticals, Inc.